Overview

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the recommended dose of CMC544 administered in combination with rituximab (R-CMC544), and in alternance with rituximab, gemcitabine and oxaliplatin (R-GEMOX) in the first phase of the study. After that, efficacy and safety of this combination will be evaluated preliminarily in patients with DLBCL in relapse or refractory, who are no candidates for autologous transplant.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Collaborator:

Pfizer

Treatments:

Gemcitabine
Inotuzumab Ozogamicin
Oxaliplatin
Rituximab